PAPILLARY THYROID CANCER
Clinical trials for PAPILLARY THYROID CANCER explained in plain language.
Never miss a new study
Get alerted when new PAPILLARY THYROID CANCER trials appear
Sign up with your email to follow new studies for PAPILLARY THYROID CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets tough thyroid cancers
Disease control OngoingThis study is testing whether combining an immunotherapy drug called PDR001 with other targeted cancer drugs is safe and effective for treating advanced thyroid cancer that no longer responds to standard radioactive iodine treatment. The trial includes 19 adults with specific typ…
Matched conditions: PAPILLARY THYROID CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
New pill tested in kids with Hard-to-Treat cancers
Disease control OngoingThis study is testing a pill called LOXO-292 in children and teenagers with advanced solid or brain tumors that have a specific genetic change called a RET alteration. The goal is to find a safe and effective dose and to see if the medicine can shrink these difficult-to-treat tum…
Matched conditions: PAPILLARY THYROID CANCER
Phase: PHASE1, PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Study tests if watching small thyroid cancers is safer than surgery
Disease control OngoingThis study follows 450 adults with very small, low-risk thyroid cancers to see which approach works better long-term: active surveillance (close monitoring without immediate surgery) or immediate thyroid removal surgery. Researchers track patients for up to 10 years to see how of…
Matched conditions: PAPILLARY THYROID CANCER
Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
One drug, many cancers: trial targets tumors by genetic fingerprint
Disease control OngoingThis study is testing a drug called entrectinib for people with advanced solid tumors that have specific genetic changes (NTRK, ROS1, or ALK gene rearrangements). It's a 'basket trial,' meaning it groups patients by their tumor's genetic type rather than where the cancer started …
Matched conditions: PAPILLARY THYROID CANCER
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC